Search results
Results from the WOW.Com Content Network
Saracatinib (AZD-0530) is an experimental drug being developed by AstraZeneca. It acts as a dual kinase inhibitor, with selective actions as a Src inhibitor and a Bcr-Abl tyrosine-kinase inhibitor. [1] [2]
Saracatinib, the first Src inhibitor to show inhibition of the Src pathway in human tumor tissue, has anti-tumor activity alone or in combination with chemotherapeutic agents. [3] Chemical structure of PP1. PP1, PP2 (kinase inhibitor) are both inhibitors of Lck and FynT. [4] [5] Dasatinib [1] [6]
TNB-486 (also known as AZD0486) [1] "is a novel CD19x CD3 bispecific T-cell engager (TCE) that incorporates a unique anti-CD3 moiety designed to reduce cytokine release syndrome by binding to T-cells with low affinity". [2]
(Reuters) -Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, Absci ...
(Reuters) -AstraZeneca said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer's early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales, as ...
Pages in category "Drugs developed by AstraZeneca" The following 133 pages are in this category, out of 133 total. This list may not reflect recent changes. A.
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows. Lindsey Leake. Updated December 20, 2024 at 7:34 PM.
It is being investigated for the treatment of cancer by AstraZeneca. [1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. [2] It has been given conditional approval for these indication in China. [3]